U.S. FDA issues warning letter to Aurobindo Pharma’s subsidiary Eugia Pharma

A formulation manufacturing unit of subsidiary Eugia Pharma Specialities near Hyderabad had earlier received four observations and an Official Action Indicated (OAI) status from the regulator